Can a pill calm the immune attack on kidneys?
NCT ID NCT05800873
First seen Aug 05, 2026 · Last updated Aug 06, 2026 · Updated 1 time
Summary
This trial tests an experimental oral drug called EVER001 in people with primary membranous nephropathy, a kidney disease where the immune system damages the kidney's filtering units, causing protein to leak into urine. The study aims to see if EVER001 can reduce proteinuria and lower harmful autoantibodies, potentially slowing disease progression. About 31 participants with biopsy-confirmed disease and high protein levels will receive the drug, with safety and effectiveness monitored over a year.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- EVER001, an oral BTK inhibitor
- What this could lead to
- If successful, EVER001 could offer a new oral treatment option to reduce proteinuria and potentially slow kidney damage in people with primary membranous nephropathy.
- What could go wrong
- This is an early-phase trial with a small number of participants, so the drug may not prove effective or safe. Possible side effects are still being evaluated.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY MEMBRANOUS NEPHROPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking University First Hospital
Beijing, China
-
Peking University Shenzhen Hospital
Shenzhen, Guangdong, China
-
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, Shanghai Municipality, China
-
Second Hospital of Shanxi Medical University
Shanxi, Taiyuan, China
-
Sichuan Province People's Hospital
Chengdu, Sichuan, China
-
Taizhou Hospital of Zhejiang Province
Taizhou, Zhejiang, China
-
The First Affiliated Hospital of Baotou Medical College
Baotou, Inner Mongolia, China
-
The First Affiliated Hospital of Medical college of Xi'an Jiaotong University
Xian, Shanxi, China
-
The First Affiliated Hospital of PLA Army Medical University
Chongqing, Chongqing Municipality, China
-
The Second Affiliated Hospital of Harbin Medical University
Harbin, Harbin, China
-
The Second Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China
-
The Second Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China
-
The Second Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
-
The Second Xiangya Hospital Of Central South University
Changsha, Changsha, China
-
The Third Affiliated Hospital,Sun Yat Sen University
Guangzhou, Guangdong, China
-
The first affliated hospital of NingBo university
Ningbo, Zhejiang, China
-
Xiangya Third Hospital, Central South University
Changsha, Hunan, China
-
Zhejiang Provincial People's Hospital
Hangzhou, Zhejiang, China
-
Zhongda Hospital Southeast University
Nanjing, Jiangsu, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can engineered immune cells tackle a tough kidney disease?
- Can a smarter antibody outsmart a kidney disease that resists standard treatment?
- Can engineered immune cells tame autoimmune kidney disease?
- Can a gene-silencing drug calm overactive complement in kidney disease?
- New gel could outperform standard therapy for kidney disease
- Immune cell therapy takes on kidney disease